These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Boerrigter G; Burnett JC Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086 [TBL] [Abstract][Full Text] [Related]
5. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798 [TBL] [Abstract][Full Text] [Related]
6. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells. Bellamy TC; Garthwaite J Br J Pharmacol; 2002 May; 136(1):95-103. PubMed ID: 11976273 [TBL] [Abstract][Full Text] [Related]
7. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies. Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881 [TBL] [Abstract][Full Text] [Related]
8. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Stasch JP; Schmidt P; Alonso-Alija C; Apeler H; Dembowsky K; Haerter M; Heil M; Minuth T; Perzborn E; Pleiss U; Schramm M; Schroeder W; Schröder H; Stahl E; Steinke W; Wunder F Br J Pharmacol; 2002 Jul; 136(5):773-83. PubMed ID: 12086987 [TBL] [Abstract][Full Text] [Related]
10. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. Becker EM; Alonso-Alija C; Apeler H; Gerzer R; Minuth T; Pleiss U; Schmidt P; Schramm M; Schröder H; Schroeder W; Steinke W; Straub A; Stasch JP BMC Pharmacol; 2001; 1():13. PubMed ID: 11801189 [TBL] [Abstract][Full Text] [Related]
11. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Mittendorf J; Weigand S; Alonso-Alija C; Bischoff E; Feurer A; Gerisch M; Kern A; Knorr A; Lang D; Muenter K; Radtke M; Schirok H; Schlemmer KH; Stahl E; Straub A; Wunder F; Stasch JP ChemMedChem; 2009 May; 4(5):853-65. PubMed ID: 19263460 [TBL] [Abstract][Full Text] [Related]
12. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Dasgupta A; Bowman L; D'Arsigny CL; Archer SL Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386 [TBL] [Abstract][Full Text] [Related]
13. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Evgenov OV; Pacher P; Schmidt PM; Haskó G; Schmidt HH; Stasch JP Nat Rev Drug Discov; 2006 Sep; 5(9):755-68. PubMed ID: 16955067 [TBL] [Abstract][Full Text] [Related]
14. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Sandner P; Stasch JP Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058 [TBL] [Abstract][Full Text] [Related]
15. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes. Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216 [TBL] [Abstract][Full Text] [Related]
16. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. Gur S; Kadowitz PJ; Hellstrom WJ Curr Pharm Des; 2010 May; 16(14):1619-33. PubMed ID: 20201788 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole]. Teixeira CE; Priviero FB; Webb RC J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702 [TBL] [Abstract][Full Text] [Related]